Author Topic: EMA to restrict use of alemtuzumab pending review  (Read 49 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8526
  • MS diagnosed 1980
  • Location: Pacific Northwest
EMA to restrict use of alemtuzumab pending review
« on: May 14, 2019, 04:34:57 pm »
The concern about stroke risk has prompted the European Medicines Agency to restrict the use of alemtuzumab pending review. From The Lancet (April 27, 2019), "Alemtuzumab to be restricted pending review, says EMA":


https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30935-3/fulltext
« Last Edit: May 14, 2019, 04:37:16 pm by agate »
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
96 Views
Last post April 16, 2016, 07:28:30 pm
by agate
0 Replies
63 Views
Last post May 26, 2016, 04:40:58 pm
by agate
0 Replies
44 Views
Last post May 02, 2018, 11:07:04 am
by agate
1 Replies
105 Views
Last post December 15, 2018, 06:55:22 am
by agate
0 Replies
25 Views
Last post September 26, 2019, 07:27:50 pm
by agate